Don’t want emails from us anymore? Click here to unsubscribe.

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today.

Rising Medtech Player (Sponsored)

This Biotech Stock Could Be Headed Higher

The medical device market is expected to surge to nearly $890B by 2032, opening massive opportunities for breakthrough technologies.
One emerging company is using perinatal tissue for advanced wound care—attracting growing investor attention.
With quarter-after-quarter revenue growth, a strong patent portfolio, and an anticipated uplisting, this medtech stock could be positioned for a major move.

Click here to see why early investors are paying attention.

Markets 📈

The market suffered hard losses today as recession fears trickle in. U.S. indexes couldn’t help but follow suit, with the Nasdaq Composite falling four whole percent.

Market-Moving News 📈

Real Estate & Mortgage

Rocket Companies Expands in Real Estate with Redfin Buyout

Rocket Companies (NYSE: RKT) is making a significant move in the real estate sector with its planned acquisition of Redfin in an all-stock deal valued at approximately $1.75 billion. The transaction is expected to expand Rocket’s footprint beyond mortgages and into home listings and brokerage services.

Redfin, known for its technology-driven home search platform and brokerage, brings over one million for-sale and rental listings to the deal. The move aligns with Rocket’s broader strategy to integrate home buying, financing, and selling under one platform, streamlining the consumer process.

The acquisition comes as the housing market faces challenges due to high borrowing costs and slowed home sales. Rocket aims to leverage Redfin’s technology and real estate services to increase its share in the home purchase market. The deal also follows broader consolidation trends in the real estate sector as companies seek to adapt to shifting consumer behavior and market conditions.

Pending regulatory and shareholder approvals, the deal is anticipated to close later this year. Market watchers are closely tracking the acquisition, as it marks one of the largest real estate deals in recent months, with potential impacts across the home buying and mortgage sectors.

Cryptocurrency

Coinbase Faces Market Pressure After Trade War Concerns Rise

Coinbase (NASDAQ: COIN) finds itself in the spotlight as its shares took a hit today, reflecting broader market unease. The cryptocurrency exchange sees investors pull back amid growing worries over an escalating trade war, a sentiment spilling over from last week. 

The company also misses out on a spot in the S&P 500 index, a decision announced late last week. Inclusion could have drawn more interest from funds and investors, but Coinbase remains on the outside. This news lands as the broader market dips, adding pressure to the exchange’s position.

Coinbase rides a wave of volatility tied to the crypto world, where shifts in Bitcoin and other digital assets often ripple through trading platforms. 

Recent data from China shows weaker demand for cryptocurrencies, a trend that weighs on companies like Coinbase. Investors notice the stock’s movement, reflecting the market’s response to these challenges.

The exchange keeps pushing forward, managing its role in a fast-changing environment. Coinbase is a key player for those eyeing crypto opportunities, balancing its operations against trade disputes and market shifts.

Energy-saving Solutions (Sponsored)

Wall Street’s Secret AI Innovator

Wall Street is taking note of a Nasdaq-listed company transforming the $124 billion smart glass industry.
With top clients like Airbus and BMW, a 59% revenue surge in 2023, and energy-saving products, this company could be the next big thing.

Discover the symbol here before the market catches on.

Pharmaceuticals

Novo Nordisk Trial Data Raises Questions on Next-Gen Weight-Loss Treatment

Novo Nordisk (NYSE: NVO) saw its stock decline after reporting updated clinical trial results for its next-generation weight-loss drug, CagriSema. The trial, which followed over 1,200 participants for over a year, showed that individuals with type 2 diabetes lost an average of 15.7% of their body weight while using the treatment.

The Danish pharmaceutical company has been positioning CagriSema as a key advancement in obesity management, following the widespread success of its weight-loss drug Wegovy. Previous trial data indicated higher weight loss percentages, and investors had been anticipating results closer to those earlier projections. 

Despite the stock’s reaction, the company emphasized that the latest findings still demonstrated significant weight reduction compared to the placebo group.

Novo Nordisk is preparing to file for regulatory approval for CagriSema and will submit applications in early 2026. The treatment combines cagrilintide with semaglutide, the active ingredient in Wegovy, and is being developed to address obesity and type 2 diabetes.

With the weight-loss drug market becoming increasingly competitive, rival companies are working to expand their offerings. Novo Nordisk recently launched an online pharmacy service to provide direct access to Wegovy at discounted prices. 

The company continues to focus on developing treatment options for obesity and metabolic conditions as demand for effective weight-loss solutions grows.

Technology (Sponsored)

The Next Wave of Market Giants Is Taking Shape

Apple. Amazon. Nvidia. Tesla. The biggest stock winners of the past decade started as under-the-radar opportunities before delivering massive gains.

Now, a new group of companies is emerging, positioned to lead the market’s next breakout phase.

(By clicking the link above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time.)

A proprietary system has identified 7 stocks with the potential to dominate in 2025, just as today’s tech giants once did.

The biggest opportunities don’t wait—position yourself before the market catches up.

Get the names and ticker symbols of all 7 stocks—100% free.

(By clicking the link above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time.)

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club